Search This Blog

Wednesday, April 24, 2013

Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma | Merck Newsroom Home

Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma | Merck Newsroom Home

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.